KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Share-based Compensation (2016 - 2025)

Novavax has reported Share-based Compensation over the past 16 years, most recently at $8.0 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $8.0 million for Q4 2025, down 23.75% from a year ago — trailing twelve months through Dec 2025 was $36.0 million (down 25.21% YoY), and the annual figure for FY2025 was $36.0 million, down 25.21%.
  • Share-based Compensation for Q4 2025 was $8.0 million at Novavax, down from $8.5 million in the prior quarter.
  • Over the last five years, Share-based Compensation for NVAX hit a ceiling of $53.1 million in Q2 2021 and a floor of $8.0 million in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $20.5 million (2023), compared with a mean of $24.2 million.
  • Biggest five-year swings in Share-based Compensation: surged 1238.21% in 2021 and later tumbled 59.66% in 2024.
  • Novavax's Share-based Compensation stood at $32.2 million in 2021, then dropped by 13.66% to $27.8 million in 2022, then plummeted by 43.63% to $15.7 million in 2023, then crashed by 33.27% to $10.4 million in 2024, then fell by 23.75% to $8.0 million in 2025.
  • The last three reported values for Share-based Compensation were $8.0 million (Q4 2025), $8.5 million (Q3 2025), and $9.2 million (Q2 2025) per Business Quant data.